These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24713929)

  • 1. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
    Xing KH; Connors JM; Lai A; Al-Mansour M; Sehn LH; Villa D; Klasa R; Shenkier T; Gascoyne RD; Skinnider B; Savage KJ
    Blood; 2014 Jun; 123(23):3567-73. PubMed ID: 24713929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
    Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
    Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
    Eichenauer DA; Bühnen I; Baues C; Kobe C; Kaul H; Greil R; Moccia A; Zijlstra JM; Hertenstein B; Topp MS; Just M; von Tresckow B; Eich HT; Fuchs M; Dietlein M; Hartmann S; Engert A; Borchmann P
    Blood; 2023 Aug; 142(6):553-560. PubMed ID: 37257195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].
    Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J
    Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
    Eichenauer DA; Engert A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features.
    El Hussein S; Fang H; Jelloul FZ; Wang W; Loghavi S; Miranda RN; Friedberg JW; Burack WR; Evans AG; Xu J; Medeiros LJ
    Arch Pathol Lab Med; 2024 Aug; 148(8):914-920. PubMed ID: 38059511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
    Fanale MA; Cheah CY; Rich A; Medeiros LJ; Lai CM; Oki Y; Romaguera JE; Fayad LE; Hagemeister FB; Samaniego F; Rodriguez MA; Neelapu SS; Lee HJ; Nastoupil L; Fowler NH; Turturro F; Westin JR; Wang ML; McLaughlin P; Pinnix CC; Milgrom SA; Dabaja B; Horowitz SB; Younes A
    Blood; 2017 Jul; 130(4):472-477. PubMed ID: 28522441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?
    Laskar S; Kumar DP; Khanna N; Menon H; Sengar M; Arora B; Gujral S; Shet T; Sridhar E; Rangarajan V; Muckaden MA; Nair R; Banavali S
    Leuk Lymphoma; 2014 Oct; 55(10):2356-61. PubMed ID: 24354681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Curr Opin Oncol; 2021 Sep; 33(5):395-399. PubMed ID: 34224482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.
    Cheng PTM; Villa D; Tonseth RP; Scott DW; Gerrie AS; Freeman CL; Pickles T; Lo AC; Farinha P; Craig JW; Slack GW; Gascoyne RD; Bénard F; Wilson D; Skinnider B; Connors JM; Sehn LH; Savage KJ
    Blood Adv; 2021 Sep; 5(18):3647-3655. PubMed ID: 34438445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
    Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
    Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.